Abzena, a Partner Research Organization for integrated discovery to GMP solutions for biologics and bioconjugates, and evitria AG, a best-in-class transient antibody expression service provider have announced their partnership to enhance lead candidate selection for large molecules. This collaboration will leverage evitria’s world-class reputation in rapid transient production of antibodies alongside Abzena’s lead candidate design and developability expertise underpinned by a comprehensive range of bioassay and analytical capabilities.
The partnership offers lead selection customers a seamless solution for fast, high quality protein with full developability characterization. Additional benefits include shortened timelines and lower costs. The data package will include an extensive set of analytics across multiple drug candidate variants to ensure confidence in selection.
Campbell Bunce, PhD, MBA, CSO of Abzena commented: “We are delighted to formalize a partnership, which has been running very successfully over multiple projects for five years. evitria shares our commitment to scientific excellence in data and reducing drug discovery timelines at lower costs. This partnership will provide a de-risked single point of contact approach to lead candidate selection allowing our partners to make more informed decisions.”
Christian Eberle, PhD, CEO of evitria said: “This partnership combines evitria’s best-in-class solution for high quality material at shortened timelines supported by Abzena’s breadth of supplementary analytical and developability services. I am delighted to offer a transformative solution to biopharma companies seeking to accelerate large molecule discovery lead selection programs.”
Abzena is a leading contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK.
Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.
For more information, please see www.abzena.com.
Founded in 2010 in Zurich, Switzerland, evitria is an expert provider of antibody expression services, with clients ranging from academic laboratories and small biotech start-ups to global biopharmaceutical companies. evitria is deeply specialized in CHO-based transient expression of antibodies, including bispecific and fusion antibodies.
For more information, please see www.evitria.com